Head-to-head data: PFVs, LNPs, and electroporation for nucleic acid delivery in cell engineering

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Head-to-head data: PFVs, LNPs, and electroporation for nucleic acid delivery in cell engineering

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Can pre-formed vesicles (PFVs) deliver better outcomes than electroporation and lipid nanoparticles (LNPs) for nucleic acid delivery in cell engineering? This session presents head-to-head comparative data across delivery platforms, covering transfection efficiency, cell viability, yield, and scalability across T cell, NK cell, and other clinically relevant cell types.

Attendees will gain a practical framework for selecting the most appropriate delivery platform based on payload type, cell type, and manufacturing context, with data drawn from mRNA, CRISPR, and DNA delivery applications in both centralized and decentralized manufacturing settings.

Attend this Live30 to:

Review comparative data demonstrating greater than 80% knockout efficiency with PFVs versus electroporation, a more than 5-fold increase in edited T cell yield by day 10, and over 85% CAR+ T cells achieved with PFVs compared to approximately 40% with LNPs
Understand how PFVs support scalable, closed manufacturing workflows, including more than 80% TCR knockout efficiency in stirred-tank bioreactor systems and more than 30% stable gene insertion in primary human T cells using a fully non-viral approach
Evaluate practical criteria for selecting between PFVs, LNPs, and electroporation based on cell type, payload, and workflow requirements
Apply instrument-free, incubation-based PFV loading to reduce formulation complexity, shorten optimization cycles, and accelerate progression from research to clinic

Register now to gain data-driven insight into how PFVs can improve cell engineering outcomes and simplify manufacturing across a range of therapeutic applications.

Sai Arun Batra, PhD

Senior Scientist, Process Development Services at Sartorius

Dr. Sai Arun Batra is a Senior Scientist in Upstream Process Development at Sartorius in Marlborough, MA. He has a background in immunology, cell therapy, and process development, with experience spanning discovery, and process optimization. He earned his PhD from Washington State University and completed postdoctoral training at Baylor College of Medicine, where he worked on autologous CAR T-cell therapies. At Sartorius, his work focuses on scalable bioreactor-based workflows for gene editing, cell therapy, and advanced therapy manufacturing.

Maria Nicla Loviglio, PhD

Manager of Scientific Support at Sartorius

Maria Nicla Loviglio, PhD earned a Master's degree in Medical Biotechnology and Molecular Medicine from the University of Bari, Italy, and a PhD in Genetics and Genomics from the University of Lausanne (UNIL, Switzerland), including a research fellowship at Duke University (Durham, US). Her academic work focused on human genetics, genomics, and neurodevelopmental disorders, resulting in several high-impact publications and prestigious research awards.

Following her PhD, Maria completed postdoctoral research at the IGBMC in Strasbourg. She joined Polyplus (now part of Sartorius) in 2020 and has since specialized in transfection and nucleic acid delivery technologies. Currently, as Manager of Scientific Support at Sartorius, she supports researchers and biopharmaceutical companies developing advanced therapies applications

You have registered for this webinar